ReviewWorld journal of gastroenterology2015
Neoplastic disease after liver transplantation: Focus on de novo neoplasms.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Pooled it
- Laparoscopic radical gastrectomy for gastric cancer following liver transplantation: a report of a rare and complex case and a multidisciplinary management strategy.Frontiers in medicine · 2026Article
- Incidence, screening, and management ofWorld journal of transplantation · 2025Review
- Frontiers and Controversies in De Novo Gastrointestinal Tumors After Organ Transplantation: Current Progress and Future Directions.Annals of surgical oncology · 2025Review
- Side Effects of Immunosuppressant Drugs After Liver Transplant.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Transabdominal Robotic-Assisted Partial Nephrectomy and CT-Guided Percutaneous Cryoablation for the Treatment of De Novo Kidney Tumors After Liver Transplantation.Life (Basel, Switzerland) · 2025Article
- De Novo Metabolic Syndrome 1 Year after Liver Transplantation and Its Association with Mid- and Long-Term Morbidity and Mortality in Liver Recipients.Journal of clinical medicine · 2024Article
- A practical approach to extrahepatic cancer screening before and after liver transplant.Clinical liver disease · 2023Review
- Main factors influencing long-term outcomes of liver transplantation in 2022.World journal of hepatology · 2023Review
- A Reduction of Calcineurin Inhibitors May Improve Survival in Patients with De Novo Colorectal Cancer after Liver Transplantation.Medicina (Kaunas, Lithuania) · 2022Article
- Face Transplant: Indications, Outcomes, and Ethical Issues-Where Do We Stand?Journal of clinical medicine · 2022Review
- Analysis of clinicopathological features of papillary thyroid carcinoma in solid organ transplant recipients: a retrospective study.Gland surgery · 2022Article
- Successful pancreatoduodenectomy ofFrontiers in surgery · 2022Article
- Characteristics and Prognosis of Colorectal Cancer after Liver or Kidney Transplantation.World journal of surgery · 2021Article
- Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group.Hepatology international · 2020Review
- Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges.Journal of clinical medicine · 2020Review
- Alcohol use disorder and liver transplant: new perspectives and critical issues.The Korean journal of internal medicine · 2020Review
- Thanatometabolomics: introducing NMR-based metabolomics to identify metabolic biomarkers of the time of death.Metabolomics : Official journal of the Metabolomic Society · 2019Article
- Totally Laparoscopic Distal Gastrectomy in Post Liver Transplant Patient.Journal of minimally invasive surgery · 2019Article
- Generic chemoprevention of hepatocellular carcinoma.Annals of the New York Academy of Sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
De novo neoplasms account for almost 30% of deaths 10 years after liver transplantation and are the most common cause of mortality in patients surviving at least 1 year after transplant. The risk of malignancy is two to four times higher in transplant recipients than in an age- and sex-matched population, and cancer is expected to surpass cardiovascular complications as the primary cause of death in transplanted patients within the next 2 decades. Since exposure to immunosuppression is associated with an increased frequency of developing neoplasm, long-term immunosuppression should be therefore minimized. Promising results in the prevention of hepatocellular carcinoma (HCC) recurrence have been reported with the use of mTOR inhibitors including everolimus and sirolimus and the ongoing open-label prospective randomized controlled SILVER. Study will provide more information on whether sirolimus-containing vs mTOR-inhibitor-free immunosuppression is more efficacious in reducing HCC recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.